Drug intelligence / Profile preview

Normosol-R

Development stage
Approved
Lead developer
ICU Medical
Modality
Small Molecules
Administration
Intravenous
01

Overview

**Normosol-R** is a sterile, nonpyrogenic, isotonic balanced crystalloid solution for intravenous fluid and electrolyte replacement. It contains sodium chloride, sodium acetate anhydrous, sodium gluconate, potassium chloride, and magnesium chloride. The product replaces extracellular fluid and provides sodium, potassium, magnesium, chloride, acetate, and gluconate ions; acetate is metabolized to bicarbonate equivalents and contributes an alkalinizing effect. It is used for acute extracellular-fluid losses associated with surgery, trauma, burns, or shock and as an adjunct for restoration of circulating volume in moderate blood loss. The current U.S. label identifies ICU Medical as the manufacturer and lists an osmolarity of approximately 295 mOsmol/L. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=0e089a44-0cee-4804-8f6f-8508508ddb5c))

Brand names
Normosol-RNormosol-R pH 7.4
Other names
multiple electrolytes injection type 1

Beyond the preview

Go deeper on Normosol-R.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Normosol-R.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call